financetom
Business
financetom
/
Business
/
Kobo Resources Reported "Significant Gold Intersections at its Kossou Gold Project
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kobo Resources Reported "Significant Gold Intersections at its Kossou Gold Project
Jul 18, 2024 7:54 AM

10:35 AM EDT, 07/18/2024 (MT Newswires) -- Kobo Resources ( KBRIF ) was edging down Thursday as it reported additional gold assay results from its inaugural diamond drill program at the Kossou Gold Project in Cote d'Ivoire.

Highlights include 2.0 metres at 7.26 g/t Au from 75.0 m and 5.0 m at 4.30 g/t Au from 178.0 m, including 1.0 m at 20.00 g/t Au from 178.0 m.

"These latest assay results from our inaugural diamond drill program at the Kossou Gold Project are a strong testament to the potential of one of Kobo's key targets, the Road Cut Zone. The strong gold intersections from three additional holes . . . confirm the presence and strength of the gold shear zone at the Road Cut Zone, especially at the southern end of the target," said Edward Gosselin, CEO.

Gosselin added: The deeper hits from drill hole KDD0017 have intersected a previously untested shear zone and highlight the depth and continuity of mineralized structures underlying the gold-in-soil geochemical anomaly at the Road Cut Zone.

"These findings support our previous 2023 drill results and strengthen our confidence in the project's overall potential, laying the groundwork for future diamond drilling initiatives. Our exploration efforts in Cote d'Ivoire continue to return strong gold assay results and we look forward to initiating a second round of diamond drill this year."

KRI was last seen down 0.005 at $0.37.

Price: 0.37, Change: -0.01, Percent Change: -1.33

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novonix Signs Testing, Development Deal With Volkswagen-Owned PowerCo
Novonix Signs Testing, Development Deal With Volkswagen-Owned PowerCo
May 15, 2024
04:32 AM EDT, 05/15/2024 (MT Newswires) -- Novonix ( NVX ) said late Tuesday it signed a non-exclusive testing and development agreement with Volkswagen-owned PowerCo to come up with synthetic graphite anode materials for electric vehicle batteries. The companies could later enter into a supply agreement for the products developed under the deal, Novonix ( NVX ) said. Financial terms...
Biogen Partner Eisai Submits FDA Biologics Application for Early Alzheimer's Self-Injection Drug
Biogen Partner Eisai Submits FDA Biologics Application for Early Alzheimer's Self-Injection Drug
May 15, 2024
04:26 AM EDT, 05/15/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said Tuesday that the latter has initiated a rolling submission of a biologics license application to the US Food and Drug Administration for lecanemab-irmb subcutaneous autoinjector as a weekly maintenance treatment for early Alzheimer's disease. The application came after the treatment, commercially known as Leqembi, was granted FDA fast-track...
New York Community Bancorp to Sell $5 Billion in Mortgage Warehouse Loans to JPMorgan Chase Bank
New York Community Bancorp to Sell $5 Billion in Mortgage Warehouse Loans to JPMorgan Chase Bank
May 15, 2024
04:12 AM EDT, 05/15/2024 (MT Newswires) -- New York Community Bancorp ( NYCB/PU ) said Tuesday it has entered into a commitment letter to sell about $5 billion in mortgage warehouse loans to JPMorgan Chase Bank. The sale is expected to close in Q3. Shares of New York Community Bancorp gained almost 6% in after-market hours on Tuesday. Price: 4.1200,...
Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
May 15, 2024
04:24 AM EDT, 05/15/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) Arcutis Biotherapeutics' ( ARQT ) shares surged more than 20% in premarket activity on Wednesday after the company reported a narrower loss and handily beat market expectations for sales. The company reported a Q1 loss late Tuesday of $0.32 per diluted...
Copyright 2023-2026 - www.financetom.com All Rights Reserved